phase 1_completion
saveTakeda Pharmaceutical Co Ltd — Cabometyx (Phase I Trial Completion)
community read0 votes
Therapy area: Oncology. Indication: Solid Tumor
Data sources
globaldata
Found something off?
drug timeline · 8
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalOct 9, 2025 · 364d ago
- approvalCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalOct 9, 2025 · 364d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalSep 10, 2025 · 393d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalMar 26, 2025 · 561d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalSep 20, 2023 · 1114d ago
- approvalCOMETRIQ (CABOZANTINIB S-MALATE) — FDA approvalAug 23, 2023 · 1142d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalFeb 13, 2023 · 1333d ago
- approvalCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalJul 14, 2022 · 1547d ago
same company · ±60 days · 1
🐶 often sniffed alongside
top 8- drugCABOMETYX97 co-mentions · 25 sources
- drugCOMETRIQ97 co-mentions · 25 sources
- tagApproval96 co-mentions · 24 sources
- drugcabozantinib48 co-mentions · 24 sources
- tagSmall Molecule48 co-mentions · 24 sources
- tagOncology2 co-mentions · 1 sources
- company$TAKTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
- company$TKPHFTAKEDA PHARMACEUTICAL CO LTD1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that